Lilly reports broader biomarker changes with combination
Eli Lilly and Company (NYSE:LLY) reported exploratory Phase 3b results from the TOGETHER-PsO study comparing Taltz plus Zepbound with Taltz alone in adults with moderate-to-severe plaque psoriasis and excess weight.











